- News / Events
- Company Information
- Financial Information
- Stock Data
- SEC Filings
- Corporate Governance
Endonovo Therapeutics (OTCQB: ENDV) is an innovative biotechnology company developing a bioelectronic approach to regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and cell death. Endonovo's Cytotronics™ platform uses our proprietary bioelectronic technology to create next-generation cell therapies and for the production of fully human biomolecules, such as cytokines and growth factors.
Our Immunotronic technology uses non-invasive electromagnetic pulses to deliver electrical stimulation via inductive coupling to the nervous system and cells. Our technology was identified in pre-clinical studies to be an innovative approach for treating acute inflammation. We are targeting inflammatory conditions in vital organs and have set the initial concentration on treating inflammation in the liver.
Our Cytotronics platform is currently being developed to create next-generation, more biologically potent cell therapies. We are currently using this technology to create an off-the-shelf therapy for the treatment of Graft-Versus-Host Disease, a rare complication following allogeneic tissue transplants, such as bone marrow and cord blood transplants, wherein immune cells in the transplanted tissue (the graft) recognize the recipient (the host) as "foreign" and begin to attack the host's cells. Acute GvHD can result in significant damage to the liver, skin, mucosa and the gastrointestinal tract and is a major issue associated with high morbidity and mortality in transplants. Our cell therapy is an HLA Double Negative (HLA -/-) cell mixture created using stem cells from the human umbilical cord and adipose tissue that does not require a tissue match.
Our mission is to save lives by treating and preventing vital organ failure using non-invasive bioelectronic medicine.